AB-PINACA
Overview[edit]
AB-PINACA is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It was originally developed by Pfizer in 2009 as part of a series of compounds related to AM-2201. AB-PINACA has been identified in synthetic cannabis products and is known for its psychoactive effects.
Chemical Structure[edit]
AB-PINACA is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide. The structure consists of an indazole core with a carboxamide group at the 3-position and a pentyl chain at the 1-position.
Pharmacology[edit]
AB-PINACA acts as a full agonist at the CB1 and CB2 cannabinoid receptors, which are part of the endocannabinoid system. This system is involved in regulating various physiological processes including mood, memory, and pain sensation. The activation of these receptors by AB-PINACA leads to its psychoactive effects.
Effects and Toxicity[edit]
The effects of AB-PINACA are similar to those of other synthetic cannabinoids, including euphoria, altered perception, and relaxation. However, it can also cause adverse effects such as anxiety, paranoia, and in some cases, severe toxicity. Overdose symptoms may include tachycardia, hypertension, and hallucinations.
Legal Status[edit]
Due to its potential for abuse and lack of medical use, AB-PINACA has been classified as a Schedule I controlled substance in many countries. This classification indicates that it is illegal to manufacture, distribute, or possess without a license.
Related Compounds[edit]
AB-PINACA is part of a larger class of synthetic cannabinoids, which includes compounds such as JWH-018, AM-2201, and UR-144. These compounds are often used in the production of synthetic cannabis products, commonly known as "spice" or "K2."
